PL2446276T3 - Sposoby określania stanu onkogennego komórki, ich zastosowania i sposoby leczenia nowotworu - Google Patents
Sposoby określania stanu onkogennego komórki, ich zastosowania i sposoby leczenia nowotworuInfo
- Publication number
- PL2446276T3 PL2446276T3 PL10745670T PL10745670T PL2446276T3 PL 2446276 T3 PL2446276 T3 PL 2446276T3 PL 10745670 T PL10745670 T PL 10745670T PL 10745670 T PL10745670 T PL 10745670T PL 2446276 T3 PL2446276 T3 PL 2446276T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- cell
- determining
- treating cancer
- oncogenic condition
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 231100000590 oncogenic Toxicity 0.000 title 1
- 230000002246 oncogenic effect Effects 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0903101A FR2947340B1 (fr) | 2009-06-25 | 2009-06-25 | Detection de l'etat oncogene de cellules humaines ou de mammiferes par presence d'un marqueur et evaluation de l'activite d'un medicament par dosage dudit marqueur |
PCT/FR2010/051320 WO2010149941A1 (fr) | 2009-06-25 | 2010-06-25 | Méthodes pour déterminer l'état oncogénique d'une cellule, leurs applications, et méthodes pour traiter le cancer |
EP10745670.9A EP2446276B9 (fr) | 2009-06-25 | 2010-06-25 | Méthodes pour déterminer l'état oncogénique d'une cellule, leurs applications, et méthodes pour traiter le cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2446276T3 true PL2446276T3 (pl) | 2015-02-27 |
Family
ID=42041623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL10745670T PL2446276T3 (pl) | 2009-06-25 | 2010-06-25 | Sposoby określania stanu onkogennego komórki, ich zastosowania i sposoby leczenia nowotworu |
Country Status (9)
Country | Link |
---|---|
US (3) | US20120100124A1 (pl) |
EP (1) | EP2446276B9 (pl) |
JP (1) | JP5765587B2 (pl) |
CN (1) | CN102498404B (pl) |
CA (1) | CA2766011A1 (pl) |
ES (1) | ES2523370T3 (pl) |
FR (1) | FR2947340B1 (pl) |
PL (1) | PL2446276T3 (pl) |
WO (1) | WO2010149941A1 (pl) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10143686B2 (en) | 2010-12-27 | 2018-12-04 | The Curators Of The University Of Missouri | Oxidosqualene cyclase as a protein target for anticancer therapeutics |
JP2015522025A (ja) * | 2012-06-27 | 2015-08-03 | ザ・キュレーターズ・オブ・ザ・ユニバーシティ・オブ・ミズーリThe Curators Of The University Of Missouri | コレステロール生合成阻害剤によるエストロゲン受容体βの誘発および癌の処置方法 |
US20140005260A1 (en) * | 2012-06-28 | 2014-01-02 | Tri-Service General Hospital | Method for inhibiting cancer metastasis by amiodarone |
AU2016347662B2 (en) * | 2015-10-27 | 2021-12-02 | Akos Biosciences, Inc. | Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer |
CN109125329A (zh) * | 2017-06-15 | 2019-01-04 | 北京蛋白质组研究中心 | C型1类尼曼-匹克蛋白抑制剂的新用途 |
CN110003303A (zh) * | 2019-05-07 | 2019-07-12 | 河南农业大学 | 胆固醇转运抑制剂的抗病毒用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993015227A1 (en) * | 1992-01-29 | 1993-08-05 | Duke University | Method of assaying for the oncogenic state of cells |
FR2838741B1 (fr) | 2002-04-19 | 2006-01-27 | Inst Nat Sante Rech Med | Derives de sterols, leur procede de preparation et medicaments les comportant |
-
2009
- 2009-06-25 FR FR0903101A patent/FR2947340B1/fr active Active
-
2010
- 2010-06-25 WO PCT/FR2010/051320 patent/WO2010149941A1/fr active Application Filing
- 2010-06-25 CA CA2766011A patent/CA2766011A1/fr not_active Abandoned
- 2010-06-25 PL PL10745670T patent/PL2446276T3/pl unknown
- 2010-06-25 EP EP10745670.9A patent/EP2446276B9/fr not_active Not-in-force
- 2010-06-25 ES ES10745670.9T patent/ES2523370T3/es active Active
- 2010-06-25 CN CN201080036000.7A patent/CN102498404B/zh not_active Expired - Fee Related
- 2010-06-25 US US13/379,143 patent/US20120100124A1/en not_active Abandoned
- 2010-06-25 JP JP2012516830A patent/JP5765587B2/ja not_active Expired - Fee Related
-
2013
- 2013-12-05 US US14/098,089 patent/US20140221353A1/en not_active Abandoned
-
2017
- 2017-01-12 US US15/404,473 patent/US20170176446A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2010149941A1 (fr) | 2010-12-29 |
US20170176446A1 (en) | 2017-06-22 |
JP2012530511A (ja) | 2012-12-06 |
CN102498404A (zh) | 2012-06-13 |
CN102498404B (zh) | 2014-11-05 |
ES2523370T3 (es) | 2014-11-25 |
FR2947340B1 (fr) | 2011-08-12 |
EP2446276B9 (fr) | 2016-05-04 |
CA2766011A1 (fr) | 2010-12-29 |
US20120100124A1 (en) | 2012-04-26 |
FR2947340A1 (fr) | 2010-12-31 |
US20140221353A1 (en) | 2014-08-07 |
EP2446276B1 (fr) | 2014-08-20 |
EP2446276A1 (fr) | 2012-05-02 |
JP5765587B2 (ja) | 2015-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20180882T1 (hr) | Sredstva za i postupci liječenja dlbcl | |
EP2335075A4 (en) | METHODS OF DETECTING CIRCULATING TUMOR CELLS | |
IL219992A0 (en) | Combination therapy for treating cancer and dianostic assays for use therein | |
PT2434891T (pt) | Métodos para tratamento de cancro e afeções não neoplásicas | |
EP2446928A4 (en) | METHOD FOR KILLING TUMOR CELLS SELECTIVELY AND APPARATUS FOR THE METHOD | |
EP2310526A4 (en) | COMPOSITIONS FOR THE DETECTION AND TREATMENT OF COLORECTAL CANCER | |
IL218987A0 (en) | Methods and compositions for treating cancer | |
EP2203746A4 (en) | SUB-POPULATIONS OF LYMPHOCYTES T CAPABLE OF TREATING CANCER | |
EP2652506A4 (en) | USE OF ANTIBODIES AGAINST CXCL16 AND CXCR6 FOR TREATMENT OR FOR THE DETECTION OF CANCER | |
EP2310006A4 (en) | TREATMENT OF CANCER | |
ZA201107879B (en) | Composition for the treatment of prostate cancer | |
EP2419136A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER | |
EP2651443A4 (en) | ANTI-CCL25 AND ANTI-CCR9 ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CANCER AND THE MIGRATION OF CANCER CELLS | |
IL219636A0 (en) | Methods and compositions for treating solid tumors and other malignancies | |
PL2446276T3 (pl) | Sposoby określania stanu onkogennego komórki, ich zastosowania i sposoby leczenia nowotworu | |
GB0804496D0 (en) | Treating cancer | |
IL210066A0 (en) | Novel ortho-aminoanilides for the treatment of cancer | |
EP2601530A4 (en) | COMPOSITIONS AND METHODS OF DETECTING, DIAGNOSING AND TREATING CANCER | |
EP2606909A4 (en) | METHOD AND COMPOSITION FOR THE TREATMENT, PREVENTION AND DIAGNOSIS OF CANCER WITH CANCER STEM CELLS OR CELLS OBTAINED THEREFROM | |
HK1161116A1 (zh) | ' - '- '- 用於腎臟細胞癌的治療的 ', '-四羥基- '-聯吡啶- '-二氧化物 | |
EP2533806A4 (en) | METHODS AND MATERIALS FOR TREATING CANCER | |
WO2011059926A9 (en) | Methods and materials for treating renal cell carcinoma | |
EP2451451A4 (en) | METHODS BASED ON HDAC 6 INHIBITOR FOR THE TREATMENT OF CANCER | |
AP2011005893A0 (en) | Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer. | |
GB0813352D0 (en) | Cancer treatment and test |